⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640792 | 1.00 | — | — | |
| SCHEMBL642477 | 1.00 | — | — | |
| SCHEMBL18074135 | 0.75 | — | — | |
| SCHEMBL18074131 | 0.75 | — | — | |
| SCHEMBL13762165 | 0.72 | — | — | |
| SCHEMBL13762169 | 0.72 | — | — | |
| SCHEMBL5028673 | 0.72 | — | — | |
| SCHEMBL12660411 | 0.69 | KDM4E (0.31) | — | |
| SCHEMBL31293584 | 0.69 | — | — | |
| SCHEMBL18911283 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118610579-A | Application of nitrogen heterocyclic compound in lithium ion battery electrolyte, lithium ion battery electrolyte and lithium ion battery | 仲恺农业工程学院 | 2024-09-06 | — | — | CN | claimed |
| EP-4685150-A1 | METHOD FOR PRODUCING AMIDE GROUP-CONTAINING COMPOUND USING N-CARBOXYAMINO ACID ANHYDRIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-01-28 | — | — | EP | disclosed |
| EP-4678240-A2 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | Hangzhou Dac Biotech Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250382307-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | IMMUNOGEN, INC. | 2025-12-18 | — | — | US | disclosed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | disclosed |
| EP-4587445-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | ImmunoGen, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250007192-A1 | METHODS FOR THE ACYLATION OF MAYTANSINOL | IMMUNOGEN, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4463461-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024225377-A1 | METHOD FOR PRODUCING AMIDE GROUP-CONTAINING COMPOUND USING N-CARBOXYAMINO ACID ANHYDRIDE | 中外製薬株式会社 | 2024-10-31 | — | — | WO | disclosed |
| US-12102689-B2 | Anti-CD22 antibody-maytansine conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-10-01 | — | — | US | disclosed |
| US-7598375-B2 | Method of acylating maytansinol with chiral amino acids | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598375-B2 | Method of acylating maytansinol with chiral amino acids | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2009004141-A2 | METHOD FOR PREPARING ENANTIOMERICALLY ENRICHED N-CARBOXYANHYDRIDE | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009004141-A2 | METHOD FOR PREPARING ENANTIOMERICALLY ENRICHED N-CARBOXYANHYDRIDE | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| US-7301019-B2 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301019-B2 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2007021674-A2 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MILLENNIUM PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MILLENNIUM PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MILLENNIUM PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |